Morgan Stanley Phathom Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 966,400 shares of PHAT stock, worth $5.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

966,400

Previous 439,490 119.89%

Holding current value

$5.48 Million

Previous $7.95 Million 1.23%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$7.45 - $18.94 $3.93 Million - $9.98 Million	526,910 Added 119.89%	966,400 $7.85 Million
Q3 2024 Nov 14, 2024	SELL	$10.25 - $19.5 $3.31 Million - $6.3 Million	-323,107 Reduced 42.37%	439,490 $7.95 Million
Q2 2024 Oct 17, 2024	BUY	$8.97 - $12.05 $4.71 Million - $6.33 Million	525,437 Added 221.55%	762,597 $7.85 Million
Q2 2024 Aug 14, 2024	BUY	$8.97 - $12.05 $4.71 Million - $6.33 Million	525,437 Added 221.55%	762,597 $7.85 Million
Q1 2024 Oct 17, 2024	SELL	$6.21 - $11.05 $3.26 Million - $5.81 Million	-525,437 Reduced 68.9%	237,160 $2.52 Million
Q1 2024 Aug 16, 2024	BUY	$6.21 - $11.05 $699,301 - $1.24 Million	112,609 Added 90.41%	237,160 $2.52 Million
Q1 2024 May 15, 2024	BUY	$6.21 - $11.05 $699,301 - $1.24 Million	112,609 Added 90.41%	237,160 $2.52 Million
Q4 2023 Aug 16, 2024	SELL	$6.99 - $10.71 $4.46 Million - $6.83 Million	-638,046 Reduced 83.67%	124,551 $1.14 Million
Q4 2023 Feb 13, 2024	BUY	$6.99 - $10.71 $323,685 - $495,947	46,307 Added 59.18%	124,551 $1.14 Million
Q3 2023 Nov 15, 2023	BUY	$10.26 - $15.7 $60,144 - $92,033	5,862 Added 8.1%	78,244 $811,000
Q2 2023 Aug 14, 2023	SELL	$7.28 - $14.32 $155,180 - $305,245	-21,316 Reduced 22.75%	72,382 $1.04 Million
Q1 2023 May 15, 2023	BUY	$6.19 - $12.36 $151,716 - $302,943	24,510 Added 35.43%	93,698 $669,000
Q4 2022 Feb 14, 2023	SELL	$9.18 - $11.53 $213,361 - $267,980	-23,242 Reduced 25.15%	69,188 $776,000
Q3 2022 Nov 14, 2022	SELL	$6.46 - $12.11 $106,150 - $198,991	-16,432 Reduced 15.09%	92,430 $1.03 Million
Q2 2022 Oct 27, 2022	BUY	$6.2 - $15.5 $150,424 - $376,061	24,262 Added 28.68%	108,862 $919,000
Q2 2022 Aug 15, 2022	BUY	$6.2 - $15.5 $150,424 - $376,061	24,262 Added 28.68%	108,862 $919,000
Q1 2022 Oct 27, 2022	SELL	$11.55 - $20.06 $280,226 - $486,695	-24,262 Reduced 22.29%	84,600 $1.15 Million
Q1 2022 May 13, 2022	SELL	$11.55 - $20.06 $630,260 - $1.09 Million	-54,568 Reduced 39.21%	84,600 $1.15 Million
Q4 2021 Feb 14, 2022	BUY	$17.83 - $33.15 $2 Million - $3.73 Million	112,435 Added 420.59%	139,168 $2.74 Million
Q3 2021 Nov 15, 2021	BUY	$30.69 - $36.83 $820,435 - $984,576	26,733 New	26,733 $857,000

Others Institutions Holding PHAT

# of Institutions

158

Shares Held

68.6M

Call Options Held

52.3K

Put Options Held

635K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $222M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account